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Purpose: Lorcaserin is a serotonin 2C receptor
agonist indicated for chronic weight manage-
ment as an adjunct to diet and exercise. The initial
approved formulation is a 10-mg, immediate-
release (IR) tablet for administration BID.
These studies investigated the single- and multiple-
dose pharmacokinetic properties of a new,
recently US Food and Drug Administration–
approved, extended-release, 20-mg once-daily
formulation.
Methods: We performed 2 separate 2-period,
2-sequence crossover studies in 36 healthy adults: a
study comparing the IR formulation to the extended-
release formulation under fasting conditions and a
study comparing the extended-release formulation
under fed and fasted conditions.
Findings: Compared with lorcaserin IR, the
Tmax after a single dose of lorcaserin extended-release
was greater (median, 12 vs 3 hours), and the Cmax
was 26% lower (38.8 vs 52.3 ng/mL). AUC
data were bioequivalent for the 2 formulations in
both single- and multiple-dose regimens, conﬁrming
no formulation effect on lorcaserin bioavailability.
In fasted and fed conditions, Tmax after a single dose
was identical (median, 12 hours), but Cmax was
approximately 45% higher in the fed state (mean,
38.5 ng/mL fasted vs 56.1 ng/mL fed). However, at
steady state, Cmax and AUC were determined to be
bioequivalent between the fasted and fed states,
indicating no clinically relevant food effect on the
pharmacokinetic properties of lorcaserin extended-
release. The safety proﬁle was consistent between the
2 formulations.
Implications: Overall, the results indicate that
lorcaserin extended-release is a suitable once-daily
alternative to the approved IR BID formulation. (Clin
Ther. 2016;38:2227–2238) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.October 2016Key words: extended-release, lorcaserin, obesity,
overweight, pharmacokinetic properties.INTRODUCTION
Obesity (body mass index [BMI] Z30 kg/m2) and
overweight (BMI Z25 and o30 kg/m2) have become
highly prevalent conditions in the United States, with
the most recent estimates indicating that 469% of
American adults are affected.1 Both obesity and
overweight are associated with increased risk of
numerous comorbidities, including cardiovascular
disease, hypertension, orthopedic disability, type 2
diabetes mellitus (T2DM), and certain cancers.2,3 As
a chronic disease, obesity requires a long-term model
of care, which has traditionally included lifestyle
interventions, such as diet and exercise.4 However,
for most patients, these lifestyle changes are often
limited in their ability to sustain clinically relevant
weight loss.4,5 For this underserved population,
adjunctive pharmacotherapy may provide a useful
weight loss option.4,5
Lorcaserin has been approved in multiple countries
as a 10-mg tablet for BID dosing and is indicated for
long-term weight management in adults with obesity
or overweight in the presence of Z1 weight-related
comorbidity as an adjunct to a reduced-calorie diet
and increased physical activity.6,7 Lorcaserin is a
highly selective serotonin (5-HT) 2C receptor agonist
that has approximately 14-fold and 61-fold greater
potency at the 5-HT2C receptor than at 5-HT2A and
5-HT2B receptors, respectively.
8 Activation of 5-HT2A2227
Clinical Therapeuticsand 5-HT2B receptors can be associated with distur-
bances in perception and cardiac valvulopathy,
respectively.9 Although the exact mechanism of action is
unknown, it is thought that lorcaserin promotes
satiety, and thereby decreases food consumption,
through the selective activation of 5-HT2C receptors
on anorexigenic pro-opiomelanocortin neurons within
the hypothalamus.10,11
The safety and efﬁcacy of lorcaserin were found in
3 Phase III studies: Behavioral Modiﬁcation and
Lorcaserin for Overweight and Obesity Management
(BLOOM), Behavioral Modiﬁcation and Lorcaserin
Second Study for Obesity Management (BLOSSOM)
in patients without T2DM, and Behavioral Modiﬁca-
tion and Lorcaserin for Obesity and Overweight
Management in Diabetes Mellitus (BLOOM-DM) in
patients with T2DM.12–14 These studies indicate that
patients receiving lorcaserin as an adjunct to a
prescribed diet and exercise program had signiﬁcantly
greater weight loss after 52 weeks than those receiving
diet and exercise counseling only (5.8% vs 2.5%,
P o 0.001 for patients without T2DM15; 4.5% vs
1.5%, P o 0.001 for patients with T2DM14).
Furthermore, more than twice as many patients
receiving lorcaserin compared with placebo achieved
weight losses of Z5% (47.1% vs 22.6%, P o 0.001
for patients without T2DM15; 37.5% vs 16.1%, P o
0.001 for patients with T2DM14) and Z10% (22.4%
vs 8.7%, P o 0.001 for patients without T2DM15;
16.3% vs 4.4%, P o 0.001 for patients with
T2DM14).
Lorcaserin is highly soluble and highly permeable,
meeting the criteria for Biopharmaceutics Classiﬁcation
System Class 1. Lorcaserin is rapidly absorbed after
oral dosing (Tmax, 1.5–2 hours)
8 and has a plasma t½
of approximately 11 hours. Lorcaserin is metabolized
in the liver by multiple human cytochrome P450
enzymes and ﬂavin-containing monooxygenase 1.8
Lorcaserin sulfamate (M1) is the major circulating
metabolite, and the N-carbamoyl glucuronide of lorca-
serin (M5) is the major excreted metabolite. Multiple
sulfotransferases and uridine 5'-diphospho-glucurono-
syltransferases are responsible for the formation of M1
and M5, respectively. These metabolites are not phar-
macologically active.8 Lorcaserin can be administered
without regard to food.
Patients with chronic diseases are likely to become
less adherent to their medication schedules over time.16
Studies have found that decreasing the frequency of2228dose administration is associated with higher adherence
rates in a variety of patient groups being treated for
different illnesses.16,17 For orally administered medica-
tions, modiﬁed-release formulations, in particular, in-
crease patient adherence for a number of chronic
conditions.18–20 Importantly, in long-term Phase III
clinical studies, population pharmacokinetic/pharmaco-
dynamic modeling revealed a highly signiﬁcant and
predictive association between probability of weight
loss and lorcaserin AUC after twice-daily adminis-
tration of an immediate-release (IR) formulation. On
the basis of this association, an extended-release
formulation that achieves bioequivalence to the IR
formulation with respect to AUC would be expected
to achieve equivalent efﬁcacy. In addition, the ﬁnd-
ing that lorcaserin Cmax values are no greater after
multiple dosing of an extended-release formulation
than the IR formulation would support a conclusion
that the safety database developed for the IR for-
mulation is relevant to the extended-release formu-
lation. The extended-release formulation of
lorcaserin was recently approved by the US Food
and Drug Administration.
Overall, the aim of pharmacokinetic/pharmacody-
namic-based bridging from the lorcaserin Phase III
program is to reveal the following: (1) an equivalent
extent of absorption of the extended-release compared
with the IR formulation based on AUC and (2) that
Cmax is not higher for the extended-release compared
with the IR formulation. In a previous Phase I study
(data on ﬁle, APD356-031), the pharmacokinetic prop-
erties of 3 prototype 20-mg lorcaserin extended-release
formulations (designated slow, medium, and fast re-
lease based on in vitro dissolution proﬁles) were
evaluated. For all extended-release formulations, tablet
dissolution was delayed by functional excipients to
modify lorcaserin release. The study found that AUC,
Cmin, and Cmax of each 20-mg lorcaserin extended-
release prototype were within target levels compared
with a single dose of the approved 10-mg IR formula-
tion. AUC of the 20-mg lorcaserin extended-release
formulation was approximately twice that of the 10-mg
IR formulation. Of the 3 prototype extended-release
formulations, the designated slow-release prototype
had the optimal characteristics (lowest Cmax, highest
Cmin, best preservation of AUC) and was selected for
further development.
We present the results of a study designed to
determine bioequivalence with respect to AUC ofVolume 38 Number 10
R. Christopher et al.20-mg lorcaserin extended-release administered once
daily compared with 10-mg lorcaserin IR BID in
healthy individuals under fasted conditions. In addi-
tion, we present the results of a second study designed
to determine the effect of a high-fat meal on the rate
and extent of absorption of 20-mg lorcaserin
extended-release once daily after a single dose and at
steady-state conditions.METHODS
Ethics
An institutional review board (IntegReview, Austin,
Texas) approved the study protocols presented here,
and each participant gave written informed consent
before any protocol-speciﬁed procedures or evalua-
tions were performed. These studies were conducted
at a single center in the United States in adherence
with the ethical principles embodied in the Declara-
tion of Helsinki.
Participants
Two studies were conducted. Study 1 compared
lorcaserin extended-release with the IR formulation in
fasted individuals. Study 2 compared lorcaserin ex-
tended-release in fasted vs fed individuals. Each study
included a unique set of 36 healthy, nonsmoking men
and women, 18 to 45 years of age, with BMIs of 18 to
45 kg/m2. Individuals were excluded if they had
previous exposure to lorcaserin; a history of severe
allergies to medications or other allergens; a history
of clinically signiﬁcant cardiovascular conditions;
uncontrolled hypertension, deﬁned as systolic blood
pressure Z140 mm Hg or diastolic blood pressure
Z90 mm Hg on 2 readings taken on 2 different days;
a recent history of major depression, anxiety, or other
psychiatric disease requiring treatment with prescrip-
tion medication; a history of chronic kidney or hepatic
disease; any clinically signiﬁcant screening laboratory
or echocardiographic abnormalities; or if prescription
or over-the-counter medications were taken within 30
days before study start or during the study (allowance
was made for acetaminophen and hormonal
contraceptives).
Study Design
Both studies were single-center, 2-treatment,
2-period, 2-sequence, randomized, single- and multi-
ple-dose, balanced crossover studies of lorcaserin inOctober 2016healthy individuals. Speciﬁc details of each study are
as follows.
Study 1
Two treatments were administered to each partic-
ipant, separated by a 5-day inpatient washout period.
Treatment A was a 1-day treatment with 10-mg
lorcaserin IR BID under fasted conditions, followed
by a 3-day washout, followed by 5 days of treatment
with 10-mg lorcaserin IR BID under fasted conditions.
Treatment B was a 1-day treatment with 20-mg
lorcaserin extended-release once daily under fasted
conditions, followed by a 3-day washout, followed by
5 days of treatment with 20-mg lorcaserin extended-
release once daily under fasted conditions. The treat-
ments were administered in 1 of 2 sequences to 18
participants each, such that each participant received
both treatments in either sequence 1 or sequence 2
(Figure 1).
Study 2
Two treatments were administered to each partic-
ipant, separated by a 5-day inpatient washout period.
Treatment A was a 1-day treatment with 20-mg
lorcaserin extended-release once daily under fasted
conditions, followed by a 3-day washout, followed by
5 days of treatment with 20-mg lorcaserin extended-
release once daily under fasted conditions. Treatment
B was a 1-day treatment with 20-mg lorcaserin
extended-release once daily under fed conditions,
followed by a 3-day washout, followed by 5 days of
treatment with 20-mg lorcaserin extended-release
once daily under fed conditions. The treatments were
administered in 1 of 2 sequences to 18 participants
each, such that each participant received both treat-
ments in either sequence 1 or sequence 2 (Figure 1).
For individuals receiving lorcaserin extended-re-
lease or IR in the fasted state, the study drug was
administered in the morning after an overnight fast
(Z10 hours); those receiving lorcaserin IR received
the second dose approximately 12 hours after the
morning dose and after having fastedZ2 hours before
the dose. Participants were maintained in the fasted
state for 4 hours after the morning dose and for
2 hours after the evening dose. For individuals receiv-
ing lorcaserin extended-release in the fed state (study 2
only), the study drug was administered in the morning
after an overnight fast (Z10 hours) and 30 minutes
after the start of a standardized high-fat meal.2229
Sequence 1
Sequence 2
TX A
TX B
Period 2Period 1
5-day TX 5-day TX
5-day TX
1-day TX
1-day TX5-day TX1-day TX
1-day TX
3-day
washout
3-day
washout
3-day
washout
washout
3-day
washout
Part 1 Part 2 Part 1 Part 2
Inpatient
5-day
Figure 1. Study design. In study 1, treatment (TX) A consisted of 10-mg lorcaserin immediate release twice
daily, and TX B consisted of 20-mg lorcaserin extended-release once daily; both TX A and B were in
the fasted state. In study 2, TX A consisted of 20-mg lorcaserin extended-release once daily in the
fasted state, and TX B consisted of 20-mg lorcaserin extended-release once daily in the fed state.
Clinical TherapeuticsThe meal consisted of 800 to 1000 total calories, with
approximately 150, 250, and 500 to 600 calories
from protein, carbohydrate, and fat, respectively;
approximately 50% of the total caloric content of
the meal was fat.
Pharmacokinetic and Statistical Analysis
For individuals in study 1 and study 2, 88 and 60
venous blood samples were withdrawn, respectively,
at regular intervals. For individuals in study 1, those
in the 1-day treatment period had 25 and 17 total
samples drawn when receiving the IR and extended-
release formulations, respectively; those in the
multiple-dose treatment period had 27 and 19 total
samples drawn when receiving the IR and extended-
release formulations, respectively. For individuals in
study 2, those in the 1-day treatment period had 14
total samples drawn in each of the fasted and fed
states; those in the multiple-dose treatment period had
16 total samples drawn in each of the fasted and fed
states.
For both studies, the plasma concentrations for
lorcaserin were measured at Tandem Labs (Salt Lake
City, Utah) using validated liquid chromatography–
tandem mass spectrometry (platform: API 5000;
ionization type: electrospray, positive and negative;
MS operation mode: selected reaction monitoring),
with a quantitation range of 0.508 to 203 ng/mL
(lower limit of quantitation, 0.508 ng/mL; assay
precision [%CV], 4.5%–6.1%; assay accuracy
[% bias], 5.8 to 1.6%). The pharmacokinetic data2230were then analyzed using WinNonlin Phoenix, version
6.4 (Pharsight Corporation, Mountain View, Califor-
nia) using appropriate noncompartmental techniques.
Cmax, Tmax, and time to ﬁrst observable plasma
concentration (Tlag) were obtained directly from
experimental observations. AUC0–t and AUC024 were
calculated using the linear trapezoidal rule. AUC01
was calculated as AUC01¼AUC0tþ Ctλz
 
, where Ct
is the last quantiﬁable lorcaserin concentration and λz
is the terminal-phase rate constant. The t1/2z was
calculated as t1=2z¼Lnð2Þ=λz. CL/F was calculated as
dose/AUC01. In addition, for study 1, ﬂuctuation
and swing parameters were analyzed. Degree of
ﬂuctuation was calculated as ﬂuctuation¼(Cmax,ss-
Cmin,ss)/Cav,ss, where Cmax,ss, Cmin,ss, and Cav,ss are
the respective steady-state measurements of Cmax,
Cmin, and average concentration (Cav). Swing was
calculated as swing¼(Cmax,ss-Cmin,ss)/Cmin,ss.
To assess the bioequivalence of lorcaserin ex-
tended-release once daily to lorcaserin IR BID in
fasted individuals (study 1) and of lorcaserin ex-
tended-release once daily in fed and fasted states
(study 2), lorcaserin Cmax and AUC parameters after
administration of a single dose or multiple doses were
analyzed using an ANOVA model appropriate for the
2-period, crossover designs of each study. Both AN-
OVA models contained factors for sequence, subject
within sequence, period, and treatment (reported in
the Appendix and Supplemental Tables I and II
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2016.08.016). AUC and Cmax geometricVolume 38 Number 10
R. Christopher et al.mean ratios (GMRs) were determined for extended-
release/IR (study 1) and fed/fasted states (study 2).
If the resulting 90% CIs were inclusive of the
prespeciﬁed 90% CI boundaries (0.800 and 1.250)
for bioequivalence, bioequivalence was claimed. In
addition, Tmax of the extended-release or IR formula-
tions in the fasted state (study 1) and of extended-
release in the fed and fasted states (study 2) were
analyzed using the Wilcoxon signed-rank test for
paired samples at the level of signiﬁcance of 0.05.
Safety
Individuals were monitored throughout the study
for adverse reactions to the study drug and proce-
dures. Safety assessments included physical examina-
tions, clinical laboratory tests, vital signs, 12-lead
ECGs, and adverse event reporting.100
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Figure 2. Mean (SD) lorcaserin immediate-re-
lease (IR) and extended-release
plasma concentration–time profiles
after single dose and at steady state
(N ¼ 34). Inset: Semi-log plot.
TX ¼ treatment.RESULTS
Baseline Characteristics
Individuals in study 1 were predominantly male
(58.3%), were predominantly black or African Amer-
ican (58.3%), and had a mean BMI of 29.3 kg/m2.
Individuals in study 2 were predominantly female
(52.8%), were predominantly white (50.0%), and
had a mean BMI of 28.5 kg/m2. A full description
of the disposition and demographic characteristics
of the study participants is given in Supplemental
Table III.
Evaluable Study Participants
A total of 36 individuals were enrolled into each
study. Thirty-four individuals in study 1 and all
individuals in study 2 completed their respective
studies. Two individuals in study 1 withdrew consent
before study completion; data from 1 of these indi-
viduals were missing a single data point only and were
therefore included in the data analysis. Data from the
other individual were incomplete, and the individual
was excluded. Relative to the rest of the study
population, as well as the entire Phase I and Phase III
population pharmacokinetic database, 1 individual in
study 1 had highly disparate drug exposures during the
IR dosing sequences, suggesting that a dose was not
taken or not absorbed. Although this patient had
normal lorcaserin exposures during the extended-
release dosing sequences, the decision was made toOctober 2016exclude this person from all primary pharmacokinetic
analyses.
Pharmacokinetic Analysis Comparing Lorcaserin
Immediate- and Extended-Release Formulations
in Fasting Participants (Study 1)
After a single dose of the IR and extended-release
formulations, the median Tmax values were 3 and 12
hours, respectively (Figure 2). Geometric mean (%CV)
Cmax values of 52.3 ng/mL (24.0%) and 38.8 ng/mL
(30.8%) and AUC0–1 values of 1240 hr  ng/mL
(24.2%) and 1217 hr  ng/mL (27.9%) were
observed for IR and extended-release formulations,
respectively (Table I). Absorption of lorcaserin from
the IR formulation was rapid, with plasma levels
observed at the ﬁrst time point taken (median Tlag, 0
hours; range, 0–0.5 hours). In contrast, the median
Tlag after administration of the extended-release for-
mulation was 0.5 hours and ranged from 0.25 to
1.5 hours.
Time to plasma steady state was achieved after 5
consecutive dosing days, irrespective of formulation.
Under steady-state conditions, the median Tmax,ss
values were 1.5 and 10 hours for the IR and
extended-release formulations, respectively (Figure 2).2231
Table I. Lorcaserin pharmacokinetic parameters after a single dose and under steady-state conditions (n ¼ 34).
Parameter
Single Dose Steady State*
IR 10 mg BID
extended-release
20 mg Once Daily IR 10 mg BID
extended-release
20 mg Once Daily
t1/2z,
† h 11.8 (1.32) 13.6 (3.34) 11.9 (1.5) 11.8 (1.48)
Tlag,
‡ h 0 (0, 0.5) 0.5 (0.25, 1.5) NA NA
Tmax,
‡ h 3 (1.5, 4) 12 (6, 16) 1.5 (1, 3) 10 (6, 12)
AUC0–1,
§ h  ng/mL 1240 (24.2) 1217 (27.9) NA NA
AUC0–24,ss,
§ h  ng/mL NA NA 1328 (26.5) 1235 (28.2)
Cmax,
§ ng/mL 52.3 (24.0) 38.8 (30.8) 80.1 (25.7) 73.9 (31.1)
CL/F,§ L/h 13.5 (25.2) 13.9 (27.9) 12.7 (26.5) 13.7 (28.2)
Fluctuation§ NA NA 0.800 (19.6) 0.824 (25.4)
Swing§ NA NA 1.26 (26.5) 1.42 (46.4)
IR ¼ immediate release; NA ¼ not applicable; Tlag ¼ time to ﬁrst observable plasma concentration.
*Steady state achieved after 5 consecutive days of dosing.
†Mean (SD).
‡Median (minimum, maximum).
§Geometric mean (%CV).
Clinical TherapeuticsGeometric mean (%CV) Cmax,ss values of 80.1 ng/mL
(25.7%) and 73.9 ng/mL (31.1%) and AUC0–24,ss
values of 1328 hr  ng/mL (26.5%) and 1235 hr  ng/
mL (28.2%) were observed for IR and extended-release
formulations, respectively (Table I). The t1/2z was not
affected by formulation type or repeat dosing, and
under steady-state conditions, the Cav was similar
between IR and extended-release dosing formulations.
Although the dosing intervals differed between the IR
and extended-release formulations (12 vs 24 hours),
both formulations were comparable with respect to
swing (1.26 [26.5%] and 1.42 [46.4%] for IR and
extended-release, respectively) and ﬂuctuation (0.800
[19.6%] and 0.824 [25.4%] for IR and extended-
release, respectively) parameters.
The GMR and associated 90% CI of the extended-
release to IR ratio for lorcaserin exposure values
AUC0–t (0.968; 90% CI, 0.931–1.007) and AUC0–1
(0.987; 90% CI, 0.948–1.028) after a single dose were
within the statistical boundaries for bioequivalence
(Figure 3 and Supplemental Table IV). At steady
state, the GMR 90% CI of both AUC0–24,ss (0.932;
90% CI, 0.891–0.975) and Cmax,ss (0.924; 90% CI,
0.876–0.975) were within the statistical boundaries2232and deemed bioequivalent (Figure 3 and Supplemental
Table IV).Pharmacokinetic Analysis Comparing the
Lorcaserin Extended-Release Formulation in
Fasted and Fed States (Study 2)
After a single dose of the 20-mg lorcaserin extended-
release formulation, the median Tmax was 12 hours in
both the fasted and fed states, indicating that food did
not affect the time to Cmax of the extended-release
formulation (Figure 4). Absorption of lorcaserin was
similar in both the fasted and fed states, with median
Tlag ranging from 0 to 2 hours (mean, 0.4 hours in the
fasted state and 0.8 hours in the fed state) for all the
study participants (Table II). Geometric mean (%CV)
Cmax values of 38.5 ng/mL (39.4%) and 56.1 ng/mL
(31.8%) and AUC0–1 values of 1141 hr  ng/mL
(48.6%) and 1332 hr  ng/mL (28.6%) were observed
for individuals in the fasted and fed states, respectively.
Elimination of lorcaserin was not affected by the
presence of food or dosing paradigm because the
mean t1/2z of lorcaserin was 13.0 hours in the fasted
state and 12.4 hours in the fed state after a single dose.Volume 38 Number 10
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Figure 3. Geometric mean ratio (GMR) (90% CI) of 20-mg extended-release/10-mg immediate release (IR)
after a single dose or multiple doses of lorcaserin (N ¼ 34). BE ¼ bioequivalence.
R. Christopher et al.Lorcaserin plasma concentrations achieved steady
state after 5 consecutive once-daily administrations of
20-mg lorcaserin extended-release under both the
fasting and fed conditions. Lorcaserin concentrations
at all time points in the steady-state interval were
similar between the fasted and fed states, suggesting
that food has no effect on the absorption or elimi-
nation of lorcaserin under steady-state conditions
(Figure 4). After multiple-dose administration of
lorcaserin extended-release, the median tmax was 10
hours in the fasted state and 12 hours in the fed state.
Geometric mean (%CV) Cmax,ss values of 69.5 ng/mL
(38.4%) and 78.7 ng/mL (30.9%) and AUC0–24,ss
values of 1216 hr  ng/mL (40.4%) and 1318 hr  ng/mL
(29.5%) were observed for individuals in fasted and
fed states, respectively (Table II). Mean t1/2z was 12.4
hours in the fasted state and 12.0 hours in the fed state
after multiple dosing. Bioequivalence between fasted
and fed states was achieved at steady state in both
Cmax,ss (GMR, 1.134; 90% CI, 1.071–1.199) and
AUC0–24,ss (GMR, 1.084; 90% CI, 1.027–1.145)
parameters (Figure 5 and Supplemental Table V).Time (d)
20-mg Lorcaserin IR 20-mg Lorcaserin 
(Fasted)
(Fed)
Extended Release
Figure 4. Mean (SD) lorcaserin extended-release
plasma concentration–time profiles
after sequential single and multiple
dosing to steady state in fasted and
fed individuals (N ¼ 36). Inset:
Semi-log plot. IR ¼ immediate release;
TX ¼ treatment.Safety
A total of 150 treatment-emergent adverse events
(TEAEs) were reported by 50 individuals (69.4%)
after administration of lorcaserin in these studies
(multiple occurrences of the same TEAE in the same
individual in the same treatment period were counted
only once) (Table III). Overall, the number of
individuals reporting TEAEs was similar between the
treatment groups in each study, and in both studies,
all TEAEs were mild to moderate in intensity; noOctober 2016serious TEAEs or deaths occurred, and no TEAE led
to study discontinuation.
In study 1, 33 TEAEs were reported by 18 indivi-
duals (50%) during treatment with lorcaserin IR, and
32 TEAEs were reported by 17 individuals (48.6%)
during treatment with lorcaserin extended-release.
More than twice as many individuals reported
headache after treatment with the IR formulation
(16 [44.4%]) than with the extended-release formulation2233
Table II. Lorcaserin extended-release pharmacokinetic parameters after a single dose and under steady-state
conditions in fasted and fed individuals (n ¼ 36).
Parameter
Single Dose Steady State
Fasted Fed Fasted Fed
t1/2z,* h 13.0 (2.44) 12.4 (2.35) 12.4 (1.94) 12.0 (1.68)
Tlag,
†,‡ h 0 (0, 2) 1 (0, 2) NA NA
Tmax,
† h 12 (6, 24) 12 (8, 16) 10 (6, 12) 12 (4, 16)
AUC0–1,
§ h  ng/mL 1141 (48.6) 1332 (28.6) NA NA
AUC0–24,
§ h  ng/mL 611 (42.9) 808 (27.7) 1216 (40.4) 1318 (29.5)
Cmax,
‡ ng/mL 38.5 (39.4) 56.1 (31.8) 69.5 (38.4) 78.7 (30.9)
NA ¼ not applicable; Tlag ¼ time to ﬁrst observable plasma concentration.
*Mean (SD).
†Median (minimum, maximum).
‡Mean Tlag is 0.4 hours in the fasted state and 0.8 hours in the fed state.
§Geometric mean (%CV).
Clinical Therapeutics(7 [20%]); dizziness was reported by more individuals
after treatment with lorcaserin extended-release
(3 [8.6%]) than lorcaserin IR (1 [2.8%]), but the
incidence was similar to what was reported in the
washout period (4 [11.1%]); reports of nausea were
generally similar between the 2 groups. Treatment-
related TEAEs were reported by fewer individuals
during treatment with lorcaserin extended-releaseAUC0-24,ss Cmax,ss
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Figure 5. Geometric mean ratio (GMR) (90% CI)
of fed/fasted after multiple doses of
20-mg lorcaserin extended-release
(N ¼ 36). BE ¼ bioequivalence.
2234than with lorcaserin IR (12 vs 18). Other common
TEAEs included constipation, somnolence, and fatigue.
Constipation was reported by 3 individuals (8.3%)
receiving lorcaserin IR and 1 individual (2.9%) receiv-
ing lorcaserin extended-release. Somnolence and fatigue
were reported by 3 (8.6%) and 2 (5.7%) subjects,
respectively, during treatment with lorcaserin extended-
release, whereas no events of somnolence or fatigue
were reported during treatment with lorcaserin IR.
In study 2, 30 TEAEs were reported by 13 individuals
(36.1%) receiving lorcaserin extended-release in the fasted
state, and 21 TEAEs were reported by 13 individuals
(36.1%) receiving lorcaserin extended-release in the fed
state. Headache was similarly reported during both the
fasted (5 [13.9%]) and fed (7 [19.4%]) treatment periods;
nausea was reported more frequently in the fasted group
(4 [11.1%]) than in the fed group (1 [2.8%]). Reports of
constipation were generally similar between the treatment
groups: 2 individuals (5.6%) in the fasted group versus 1
individual (2.8%) in the fed group. Other common
TEAEs included abdominal pain (3 individuals [8.3%]
in the fasted group vs 0 in the fed group) and back pain
(1 individual in each treatment group).DISCUSSION
The results of the 2 studies presented here indicate
that, under fasting conditions, a 20-mg lorcaserin
extended-release formulation administered once dailyVolume 38 Number 10
Table III. Number (percentage) of TEAEs reported in Z5% of individuals in any treatment group in either study.*
Category
Study 1 Study 2
Treatment A
(IR) (n ¼ 36)
Treatment B
(extended-
release)
(n ¼ 35)
Washout
(n ¼ 36)
All
(N ¼ 36)
Treatment A
(extended-release
Fasted) (n ¼ 36)
Treatment B
(extended-release
Fed) (n ¼ 36)
Washout
(n ¼ 36)
All
(N ¼ 36)
Total
(N ¼ 72)
Individuals reporting
TEAEs
18 (50) 17 (48.5) 10 (27.8) 28 (77.8) 13 (36.1) 13 (36.1) 10 (27.8) 22 (61.1) 50 (69.4)
Gastrointestinal disorders
Abdominal pain 1 (2.8) 1 (2.9) 1 (2.8) 3 (8.3) 3 (8.3) 0 (0.0) 0 (0.0) 3 (8.3) 6 (8.3)
Constipation 3 (8.3) 1 (2.9) 0 (0.0) 4 (11.1) 2 (5.6) 1 (2.8) 1 (2.8) 4 (11.1) 8 (11.1)
Nausea 2 (5.6) 1 (2.9) 3 (8.3) 6 (16.7) 4 (11.1) 1 (2.8) 1 (2.8) 5 (13.9) 11 (15.3)
General disorders and administration site conditions
Fatigue 0 (0.0) 2 (5.7) 0 (0.0) 2 (5.6) 0 (0.0) 1 (2.8) 0 (0.0) 1 (2.8) 3 (4.2)
Metabolism and nutrition disorders
Decreased appetite 0 (0.0) 1 (2.9) 1 (2.8) 2 (5.6) 2 (5.6) 1 (2.8) 1 (2.8) 4 (11.1) 6 (8.3)
Musculoskeletal and connective tissue disorders
Back pain 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 1 (2.8) 1 (2.8) 3 (8.3) 3 (4.2)
Flank pain 1 (2.8) 1 (2.9) 0 (0.0) 2 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.8)
Myofascial pain
syndrome
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 1 (2.8) 0 (0.0) 2 (5.6) 2 (2.8)
Nervous system disorders
Dizziness 1 (2.8) 3 (8.6) 4 (11.1) 6 (16.7) 1 (2.8) 1 (2.8) 0 (0.0) 2 (5.6) 8 (11.1)
Headache 16 (44.4) 7 (20.0) 4 (11.1) 19 (52.8) 5 (13.9) 7 (19.4) 1 (2.8) 12 (33.3) 31 (43.0)
Presyncope 0 (0.0) 1 (2.9) 1 (2.8) 2 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.8)
Somnolence 0 (0.0) 3 (8.6) 0 (0.0) 3 (8.3) 1 (2.8) 0 (0.0) 1 (2.8) 1 (2.8) 4 (5.6)
Psychiatric disorders
Abnormal dreams 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 2 (5.6) 2 (5.6) 2 (2.8)
Euphoric mood 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 1 (2.8) 0 (0.0) 2 (5.6) 2 (2.8)
Irritability 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 1 (2.8) 2 (5.6) 2 (2.8)
IR ¼ immediate release; TEAE ¼ treatment-emergent adverse event.
*Multiple occurrences of TEAEs by the same individual in the same treatment group were counted only once.
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Clinical Therapeuticsis bioequivalent with respect to AUC to the cur-
rently marketed 10-mg lorcaserin IR formulation
administered BID and that bioequivalence was
achieved between fed and fasted conditions. Although
these studies did not directly address the efﬁcacy of the
extended-release formulation, in Phase III clinical
studies of lorcaserin IR, pharmacokinetic/pharmaco-
dynamic modeling revealed a predictive relationship
between lorcaserin AUC and probability of achieving
weight loss,21 indicating that an AUC-bioequivalent
extended-release formulation would be expected to
have equivalent efﬁcacy in weight loss. Furthermore,
there is no evidence from the pharmacokinetic analysis
that suggests the extended-release formulation would
behave differently in the target population. The
exposure-response relationship established for lorca-
serin is independent of Cmax; therefore, Cmax was not
used as a necessary criterion for IR–extended-release
bioequivalence. However, for safety purposes, Cmax
was evaluated, and it was conﬁrmed that the Cmax of
lorcaserin extended-release was similar to or lower
than that of lorcaserin IR. This ﬁnding conﬁrms the
relevance of the safety database developed based on
the IR formulation for reference to the extended-
release formulation.
Absorption of lorcaserin into the systemic circulation
as measured by Tmax was signiﬁcantly slower than that
of the IR formulation after both single-dose and
multiple-dose administrations. The extended-release
and IR formulations were determined to be bioequiva-
lent based on AUC after single doses under fasting
conditions; furthermore, in a multiple-dosing regimen,
the 2 formulations were found to be bioequivalent by
both Cmax and AUC parameters in fasting individuals.
Evaluation of modiﬁed-release formulations in
fasted and fed states is important for identifying any
potential safety risk from the co-administration of
medications with food, which can result in the dose
being more rapidly released compared with fasted
conditions.22 There was no evidence of dose dumping
in this study. Although food slightly increased the
extent of drug absorption in both single-dose and
multiple-dose treatments, co-administration of the lor-
caserin extended-release tablet with a high-fat meal did
not alter Tmax, either after a single dose or under
steady-state conditions. After a single dose of lorcaserin
extended-release, the mean Cmax was approximately
46% higher after a standard high-fat meal compared
with fasting conditions, and mean AUC values,2236although slightly higher with food, achieved bioequi-
valence with respect to AUC0–1. However, under
steady-state dosing conditions, bioequivalence in both
Cmax and AUC0–24 parameters was achieved for the
extended-release formulation between fed and fasted
conditions. Therefore, although there was a small effect
of a high-fat, high-calorie meal on lorcaserin pharma-
cokinetic properties after a single dose of the extended-
release formulation, the results at steady state indicate
that the difference is not clinically meaningful.
Both the 10-mg lorcaserin IR and 20-mg lorcaserin
extended-release formulations were generally well tol-
erated by individuals in these studies. In study 1, the
number of individuals reporting TEAEs was similar
during treatment with the IR and extended-release
formulations of lorcaserin (18 vs 17). However,
treatment-related TEAEs were reported by fewer indi-
viduals during treatment with the extended-release
formulation compared with the IR formulation (12 vs
18). This difference is primarily accounted for by the
fewer incidences of headache reported by individuals
taking the extended-release formulation (7 vs 16) and
may be the result of the lower mean Cmax and longer
Tmax of the extended-release formulation relative to the
IR formulation. Adverse events related to gastrointesti-
nal disorders also occurred less frequently with the
extended-release formulation compared with the IR
formulation. In study 2, the number of individuals
reporting TEAEs was the same between the treatment
groups (13 each), but the number of TEAEs reported by
individuals in the fasted state was higher than that
reported by individuals in the fed state (30 vs 21). This
difference could be largely accounted for by the greater
number of individuals reporting TEAEs related to
gastrointestinal disorders in the fasted state (11 vs 3 in
the fed state). Most TEAEs across both studies were
related to the System Organ Classes of nervous system
disorders (headache, dizziness) and gastrointestinal dis-
orders (nausea, constipation), consistent with earlier
trials of lorcaserin IR.
A potential limitation of the data presented here is
the disparity in the demographic characteristics be-
tween the 2 studies, as well as compared with the
general population. Individuals self-reported as black
or African American were overrepresented by approx-
imately 4-fold when compared with the most recent
US Census information.23 Although these studies
on lorcaserin extended-release were not powered
to detect exposure differences among individuals ofVolume 38 Number 10
R. Christopher et al.different ethnicities, we consider that such differences
are unlikely to manifest themselves because previous
pharmacokinetic studies have found that plasma
concentrations do not differ among racial subgroups
after exposure to lorcaserin IR.13,24CONCLUSIONS
The results of these studies indicate that the 20-mg
lorcaserin extended-release formulation is bioequiva-
lent to the commercially available IR tablet and may
be dosed without regard to food. The lorcaserin
extended-release formulation was generally well tol-
erated in this sample of healthy adults and is expected
to maintain the safety and efﬁcacy proﬁle of the IR
formulation while theoretically improving patient
adherence with the prescribed dosing regimen for
weight management. The development of a lorcaserin
extended-release formulation enables the possibility of
changing the therapeutic dosing regimen from BID to
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Figure S1 and Tables SI-SV.ANOVA analyses for Study 1
ANOVA comparison of lorcaserin pharmacoki-
netic parameters showed no signiﬁcant difference
between sequence (AUC and Cmax) or treatment
(AUC only) after single doses, suggesting that AUC
was similar, independent of which formulation was
dosed ﬁrst in fasting subjects (Supplementary Table SI).
As the extended-release formulation was designed to
produce a lower Cmax compared to the IR formulation,
a signiﬁcant treatment effect (Po0.0001) was seen in
Cmax values between extended-release and IR treat-
ments. There was no apparent pharmacokinetic carry-
over effect, as the pre-dose lorcaserin concentrations
prior to period 2 were below the limit of quantitation
or less than 5% of Cmax.
After multiple-dose treatment in fasting subjects,
ANOVA comparison results showed no signiﬁcant
difference between treatment sequence or period
effects in either AUC0-24,ss or Cmax,ss (Supplementary
Table SI).
IR and extended-release formulation median tmax
values were signiﬁcantly different in both single-dose1.5
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Supplementary Figure S1. Geometric Mean Ratio
(90% CI) of Fed/
Fasted Following a
Single Dose of 20-mg
Lorcaserin extended-
release (N¼36).
October 2016and steady-state regimens, as determined by a Wil-
coxon signed-rank test (Supplementary Table SI). As
expected for the extended-release formulation, ab-
sorption of lorcaserin into the systemic circulation
was slower than that of the IR formulation.
ANOVA analyses for Study 2
ANOVA comparison of lorcaserin pharmacoki-
netic parameters Cmax, Cmax,ss, AUC0-t, AUC0-1,
and AUC0-24 following single- and multiple-dose
treatments of lorcaserin extended-release in fed and
fasted subjects showed a statistically signiﬁcant
(Po0.05) effect of sequence, potentially confounding
the treatment (food) effect (Supplementary Table SII).
Pharmacokinetic carryover, insufﬁcient dosing to
reach steady state, selection bias due to
randomization issues, and the impact of outliers
were all explored as potential factors, but none
appeared to be major contributors to the observed
sequence effect. As both sequences were comparable
and consistent with regard to the food effect on
lorcaserin absorption, the observed sequence effect
may reﬂect the high power of the study to detect a
small quantitative difference of minimal clinical
importance.
A Wilcoxon signed-rank test showed that there was
no statistically signiﬁcant difference between the tmax
values in fasted and fed states across dosing para-
digms following oral administration of 20-mg lorca-
serin extended-release QD (Supplementary Table SII).
Food, therefore, does not affect the rate or extent of
lorcaserin absorption from the extended-release
formulation.
Analysis of bioequivalence after single doses in
Study 2
Bioequivalence between fasted and fed states using
Cmax (GMR, 1.459; 90% CI [1.345, 1.581]) and
AUC0-t (GMR, 1.179; 90% CI [1.103, 1.260]) was
not achieved after a single dose. However, by extrap-
olating to inﬁnity (AUC0-1) and thereby capturing
greater than 90% of the exposure, bioequivalence was
achieved between fasted and fed states (GMR, 1.167;
90% CI [1.092, 1.247]) (Supplementary Figure S1).2238.e1
Supplementary Table SI. Analysis of Lorcaserin Pharmacokinetic Parameters in Study 1: 20-mg Lorcaserin
extended-release versus 10-mg Lorcaserin IR in Fasting Subjects (N¼34)
Parameter
P Values
Sequence Effect Treatment Effect Period Effect
Single dose
AUC0-1 (hr  ng/mL)* 0.671 0.597 0.0001
AUC0-t (hr  ng/mL)* 0.705 0.175 o0.0001
Cmax (ng/mL)
* 0.512 o0.0001 0.0006
Tmax (h)
† o0.0001
Multiple dose
AUC0-24 (hr  ng/mL)* 0.427 0.0130 0.247
Cmax,ss (ng/mL)
* 0.483 0.0184 0.173
Tmax (h)
† o0.0001
ANOVA¼analysis of variance; AUC0-1¼area under the plasma concentration–time curve from time zero to inﬁnity;
AUC0-t¼area under the plasma concentration–time curve from time zero to the time of the last quantiﬁable plasma
concentration; AUC0-24¼area under the plasma concentration–time curve from time zero to 24 hours at steady state;
Cmax¼maximum plasma concentration; Cmax,ss¼maximum plasma concentration at steady state; IR¼immediate release;
Tmax¼time to maximum plasma concentration.
*Values from ANOVA analysis.
†Values from Wilcoxon signed-rank test.
Supplementary Table SII. Analysis of Lorcaserin Pharmacokinetic Parameters in Study 2: 20-mg Lorcaserin
extended-release in Fasting Versus Fed Subjects (N¼36)
Parameter
P Values
Sequence Effect Treatment Effect Period Effect
Single dose
AUC0-1
* 0.0212 0.0004 0.0141
AUC0-t
* 0.0230 0.0002 0.0133
Cmax
* 0.0403 o0.0001 0.1200
tmax
† 0.1820
Multiple dose
AUC0-24,ss
* 0.0086 0.017 0.0021
Cmax,ss
* 0.0308 0.0006 0.0027
tmax
† 0.1539
ANOVA¼analysis of variance; AUC0-1¼area under the plasma concentration–time curve from time zero to inﬁnity;
AUC0-t¼area under the plasma concentration–time curve from time zero to the time of the last quantiﬁable plasma
concentration; AUC0-24,ss¼ area under the plasma concentration–time curve from time zero to 24 hours at steady state;
Cmax¼maximum plasma concentration; Cmax,ss¼maximum plasma concentration at steady state; IR¼immediate release;
tmax¼time to maximum plasma concentration.
*Values from ANOVA analysis.
†Values from Wilcoxon signed-rank test.
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Supplementary Table SIII. Summary of Subject Disposition and Demographics by Study and Treatment Sequence
Study 1 (Lorcaserin extended-release vs
Lorcaserin IR)
Study 2 (Food Effect on Lorcaserin extended-
release)
All (N¼36)
Sequence*
All (N¼36)
Sequence†
AB (N¼18) BA (N¼18) AB (N¼18) BA (N¼18)
Sex, n (%)
Male 21 (58.3%) 11 (61.1%) 10 (55.6%) 17 (47.2%) 10 (55.6%) 7 (38.9%)
Female 15 (41.7%) 7 (38.9%) 8 (44.4%) 19 (52.8%) 8 (44.4%) 11 (61.1%)
Age (years)‡ 33.14 (1.14) 33.00 (1.65) 33.28 (1.62) 33.92 (1.19) 34.17 (1.57) 33.67 (1.83)
Race, n (%)
American Indian or Alaska Native 1 (2.8%) 1 (5.6%) 0 (0.0%) 1 (2.8%) 1 (5.6%) 0 (0.0%)
Black or African American 21 (58.3%) 11 (61.1%) 10 (55.6%) 16 (44.4%) 6 (33.3%) 10 (55.6%)
White 14 (38.9%) 6 (33.3%) 8 (44.4%) 18 (50.0%) 10 (55.6%) 8 (44.4%)
Other 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.8%) 1 (5.6%) 0 (0.0%)
Height (cm) 166.45 (2.00) 167.53 (2.84) 165.37 (2.88) 168.69 (1.63) 169.25 (2.26) 168.14 (2.41)
Weight (kg) 80.94 (2.95) 82.29 (4.36) 79.58 (4.07) 81.51 (2.96) 85.77 (4.05) 77.26 (4.18)
BMI (kg/m2) 29.27 (1.01) 29.43 (1.57) 29.11 (1.32) 28.49 (0.82) 29.78 (1.10) 27.20 (1.16)
Completers, n (%) 34 (94.4%) 17 (94.4%) 17 (94.4%) 36 (100%) 18 (100%) 18 (100%)
Subjects withdrawn due to withdrawal of
informed consent, n (%)
2 (5.6%) 1 (5.6%) 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
AB¼treatment A before treatment B; BA¼treatment B before treatment A; BMI¼body mass index; IR¼immediate release.
*In Study 1, Treatment A consisted of 1 day of treatment with 10-mg lorcaserin IR twice daily followed by a 3-day washout before 5 days of treatment with 10-mg
lorcaserin IR twice daily under fasted conditions. Treatment B consisted of 1 day of treatment with 20-mg lorcaserin extended-release once daily followed by a 3-day
washout before 5 days of treatment with 20-mg lorcaserin extended-release once daily under fasted conditions.
†In Study 2, Treatment A consisted of 1 day of treatment with 20-mg lorcaserin extended-release once daily in the fasted state followed by a 3-day washout before 5
days of treatment with 20-mg lorcaserin extended-release once daily in the fasted state. Treatment B consisted of 1 day of treatment with 20-mg lorcaserin extended-
release once daily in the fed state followed by a 3-day washout before 5 days of treatment with 20-mg lorcaserin extended-release once daily in the fed state.
‡All statistics are presented as mean (standard error of the mean) unless otherwise noted.
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Supplementary Table SIV. Bioequivalence Determination Between Immediate-Release and Extended-Release
Lorcaserin Formulations (N¼34)
Parameter
Geometric Mean
20 mg extended-release QD 10 mg IR BID GMR* 90% CI†
Single dose
AUC0-1 (hr  ng/mL) 1219 1235 0.987 (0.948, 1.028)
AUC0-t (hr  ng/mL) 1169 1207 0.968 (0.931, 1.007)
Cmax (ng/mL) 39.0 52.2 0.748 (0.705, 0.793)
Steady state
AUC0-24,ss (hr  ng/mL) 1234 1324 0.932 (0.891, 0.975)
Cmax,ss (ng/mL) 73.8 79.9 0.924 (0.876, 0.975)
AUC0-1¼area under the plasma concentration–time curve from time zero to inﬁnity; AUC0-24,ss¼area under the plasma
concentration–time curve from time zero to 24 hours post-dose at steady state; BID¼twice daily; CI¼conﬁdence interval;
Cmax¼maximum plasma concentration; Cmax,ss¼maximum plasma concentration at steady state; GMR¼geometric mean
ratio; IR¼immediate release; QD¼once daily.
*Geometric mean of the test/reference (20 mg extended-release QD/10 mg IR BID) ratio.
†Lower and upper limits of 90% conﬁdence interval on the GMR.
Supplementary Table SV. Bioequivalence Determination of Extended-Release Lorcaserin Formulation in
Fasting and Fed States (N¼36)
Parameter
Geometric Mean
GMR* 90% CI†Fed State Fasting State
Single dose
AUC0-1 (hr  ng/mL) 1332 1141 1.167 (1.092, 1.247)
AUC0-t (hr  ng/mL) 1294 1097 1.179 (1.103, 1.260)
Cmax (ng/mL) 56.1 38.5 1.459 (1.345, 1.581)
Steady state
AUC0-24,ss (hr  ng/mL) 1318 1216 1.084 (1.027, 1.145)
Cmax,ss (ng/mL) 78.7 69.5 1.134 (1.071, 1.199)
AUC0-1¼area under the plasma concentration–time curve from time zero to inﬁnity; AUC0-t¼area under the plasma
concentration–time curve from time zero to the time of the last quantiﬁable plasma concentration; AUC0-24,ss¼area under
the plasma concentration–time curve from time zero to 24 hours post-dose at steady state; CI¼conﬁdence interval;
Cmax¼maximum plasma concentration; Cmax,ss¼maximum plasma concentration at steady state; GMR¼geometric
mean ratio.
*Geometric mean of the test/reference (Fed State/Fasting State) ratio.
†Lower and upper limits of 90% conﬁdence interval on the GMR.
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